tbuckley/cabot-search huggingface dataset:
Effect of Cilnidipine on Left Ventricular Diastolic Function in Hypertensive Patients as Assessed by Pulsed Doppler Echocardiography and Pulsed Tissue Doppler Imaging
Authors: Yukiko Onose, Takashi Oki, Hirotsugu Yamada, Kazuyo Manabe, Yoshimi Kageji, Masako Matsuoka, Takashi Yamamoto, Tomotsugu Tabata, Tetsuzo Wakatsuki, Susumu Ito
Journal: Circulation (2001)

The purpose of the present study was to examine the mechanisms of improvement in left ventricular (LV) diastolic function in hypertensive patients treated with cilnidipine, a new and unique calcium antagonist that has both L-type and N-type voltage-dependent calcium channel blocking actions, using pulsed Doppler echocardiography and pulsed tissue Doppler imaging. The study comprised 35 untreated patients with essential hypertension (19 men and 16 women; mean age 65+/-10 years). The peak early diastolic and atrial systolic transmitral flow velocities (E and A, respectively) and their ratio (E/A), and the peak early diastolic and atrial systolic motion velocities (Ew and Aw, respectively) of the LV posterior wall and their ratio (Ew/Aw) were determined in all patients before and after 1, 3 and 6 months on cilnidipine (10 mg/day). One month: Systolic and diastolic blood pressures were significantly decreased. E and E/A were significantly increased, whereas there were no significant changes in Ew and Ew/Aw. Three months: Ew and Ew/Aw were significantly increased compared to those before and 1 month after cilnidipine. Six months: E and E/A were significantly increased compared with before and 3 months after cilnidipine, and Ew and Ew/Aw were significantly increased compared with before cilnidipine. Moreover, the LV mass index was significantly decreased compared to that before cilnidipine. In summary, changes in LV diastolic performance in patients with essential hypertension following cilnidipine treatment were biphasic with an initial increase in early diastolic transmitral flow velocity and a later increase in early diastolic LV wall motion velocity. The initial and later changes can be related to an acute change in afterload and a later improvement in LV relaxation.
Atypical BCR-ABL Transcripts Chronic Myelogenous Leukemias Show Particular Features, and Their Classical Worse Prognosis Seems Abrogated by Imatinib Mesylate. A Retrospective Analysis of 22 Patients, on the Behalf of the French Intergroup of CML (Fi(ϕ)-LMC Group).
Authors: Franck E. Nicolini, Nathalie Grardel, Sandrine Hayette, Jean-Michel Cayuela, Agnès Buzyn, Eric Delabesse, Christian Bastard, Odile Blanchet, Nathalie Sorel, Marie-Josée Mozziconacci, Ali Turhan, Virginie Eclache, François-Xavier Mahon, Nicole Dastugue, Eric Legac, Marie-Pierre Gaub, Sélim Corm, Claude Preudhomme
Journal: Blood (2005)
Disruption of Acetyl-Lysine Turnover in Muscle Mitochondria Promotes Insulin Resistance and Redox Stress without Overt Respiratory Dysfunction
Authors: Ashley S. Williams, Timothy R. Koves, Michael T. Davidson, Scott B. Crown, Kelsey H. Fisher-Wellman, Maria J. Torres, James A. Draper, Tara M. Narowski, Dorothy H. Slentz, Louise Lantier, David H. Wasserman, Paul A. Grimsrud, Deborah M. Muoio
Journal: Cell Metabolism (2019)
Spatial Mapping of Myelopoiesis Reveals the Bone Marrow Niche for Monocyte Dendritic Cell Progenitors
Authors: Jizhou Zhang, Qingqing Wu, Courtney Johnson, André Olsson, Anastasiya Slaughter, Margot Lindsay May, Benjamin Weinhaus, Emily Bowers, James Douglas Engel, Jean X. Jiang, Sherry L. Abboud-Werner, Nathan Salomonis, H. Leighton Grimes, Daniel Lucas-Alcaraz
Journal: Blood (2019)
The Novel, Orally Active Proteasome Inhibitor, NPI-0052, Induces Apoptosis in Leukemia Lymphoma Cell Lines and Patient Specimens.
Authors: Claudia P. Miller, Kechen Ban, Stacey L. Ruiz, Saskia Neuteboom, Michael Palladino, David McConkey, Joya Chandra
Journal: Blood (2005)
Molecular basis of bacterial disinfectant resistance
Authors: Samantha Mc Carlie, Charlotte E. Boucher, Robert R. Bragg
Journal: Drug Resistance Updates (2019)

Antibiotic resistance could accelerate humanity towards an already fast-approaching post-antibiotic era, where disinfectants and effective biosecurity measures will be critically important to control microbial diseases. Disinfectant resistance has the potential to change our way of life from compromising food security to threatening our medical health systems. Resistance to antimicrobial agents occurs through either intrinsic or acquired resistance mechanisms. Acquired resistance occurs through the efficient transfer of mobile genetic elements, which can carry single, or multiple resistance determinants. Drug resistance genes may form part of integrons, transposons and insertions sequences which are capable of intracellular transfer onto plasmids or gene cassettes. Thereafter, resistance plasmids and gene cassettes mobilize by self-transmission between bacteria, increasing the prevalence of drug resistance determinants in a bacterial population. An accumulation of drug resistance genes through these mechanisms gives rise to multidrug resistant (MDR) bacteria. The study of this mobility is integral to safeguard current antibiotics, disinfectants and other antimicrobials. Literature evidence, however, indicates that knowledge regarding disinfectant resistance is severly limited. Genome engineering such as the CRISPR-Cas system, has identified disinfectant resistance genes, and reversed resistance altogether in certain prokaryotes. Demonstrating that these techniques could prove invaluable in the combat against disinfectant resistance by uncovering the secrets of MDR bacteria.
SAT0118 Meralgia parasthetica in pregnancy
Authors: MK Al-Izzi, A Sabri, L Saed
Journal: Annals of the Rheumatic Diseases (2001)

<h3>Background</h3> <h3>Objectives</h3> To study the association between pregnancy and meralgia paresthetica (mp), the entrapment neuropathy of the lateral femoral cutaneous nerve (LFCN). <h3>Methods</h3> Three hundred and forty pregnant women were surveyed by history and clinncal examination in 3 major obsterric centres in baghdad for the presence of underlying mp and compared to a control group of 200 non-pregnant females. <h3>Results</h3> Thirteen pregnant women were found to have MP (3.8%) in contrast to only one out of 200 non-pregnant women in the control group (0.5%), which was significant stastically (P = 0.019). Most of the cases were in their third trimester (53.8%), then in the second trimester (38.5%), while only 7.7% of cases in the first trimester. <h3>Conclusion</h3> MP in pregnancy is not a rare disorder but is often misfiagnosed. The aetiological factors in pregnancy may be mechanical and/or anatomical variations of the LFCN. However, this study disproves neither a hormonal nor a hereditary role in the causation of the disorder.
Single agent talacotuzumab demonstrates limited efficacy but considerable toxicity in elderly high-risk MDS or AML patients failing hypomethylating agents
Authors: Anne Sophie Kubasch, Freya Schulze, Aristoteles Giagounidis, Katharina S. Götze, Jan Krönke, Katja Sockel, Jan Moritz Middeke, Fatiha Chermat, Silke Gloaguen, Martin Puttrich, Carmen Weigt, Doreen William, Pierre Fenaux, Richard F. Schlenk, Christian Thiede, Sebastian Stasik, Anna Mies, Lionel Adès, Uta Oelschlägel, Uwe Platzbecker
Journal: Leukemia (2019)
Integrated Immune Signature Analyses Identifies Evolution of Distinct Immunoregulatory Cell Populations Which Control Alloreactivity after Allogeneic HSCT
Authors: James Aries, Sarah Charrot, Jennifer Ball, Matthew Mee, Symeon Theocharidis, Sofie Van Gassen, Sameena Iqbal, John G. Gribben, Jeff Davies
Journal: Blood (2019)
Treatment of Older Patients With Mantle Cell Lymphoma (MCL): Long-Term Follow-Up of the Randomized European MCL Elderly Trial
Authors: Hanneke C. Kluin-Nelemans, Eva Hoster, Olivier Hermine, Jan Walewski, Christian H. Geisler, Marek Trneny, Stephan Stilgenbauer, Florian Kaiser, Jeanette K. Doorduijn, Gilles Salles, Michal Szymczyk, Hervé Tilly, Lothar Kanz, Christian Schmidt, Pierre Feugier, Catherine Thieblemont, Josée M. Zijlstra, Vincent Ribrag, Wolfram Klapper, Christiane Pott, Michael Unterhalt, Martin H. Dreyling
Journal: Journal of Clinical Oncology (2019)

In an update of the randomized, open-label, phase III European Mantle Cell Lymphoma (MCL) Elderly trial (ClinicalTrials.gov identifier: NCT00209209), published in 2012, we aimed to confirm results on long-term outcome focusing on efficacy and safety of long-term use of rituximab maintenance.Five hundred sixty patients with newly diagnosed MCL underwent a first random assignment between rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) and rituximab, fludarabine, and cyclophosphamide (R-FC) induction, followed by a second random assignment in 316 responders between rituximab and interferon alfa maintenance, to be continued until progression. We compared progression-free survival from the second randomization and overall survival (OS) from the first or second randomizations.After a median follow-up time of 7.6 years, the previously described difference in OS between the induction arms persisted (median, 6.4 years after R-CHOP [n = 280] v 3.9 years after R-FC [n = 280]; P = .0054). Patients responding to R-CHOP had median progression-free survival and OS times of 5.4 and 9.8 years, respectively, when randomly assigned to rituximab (n = 87), compared with 1.9 years (P < .001) and 7.1 years (P = .0026), respectively, when randomly assigned to interferon alfa (n = 97). In 58% and 32% of patients treated with R-CHOP, rituximab maintenance was still ongoing 2 and 5 years from start of maintenance, respectively. After R-FC, rituximab maintenance was associated with an unexpectedly high cumulative incidence of death in remission (22% at 5 years). Toxicity of rituximab maintenance was low after R-CHOP (grade 3-4 leukopenia or infection < 5%) but more prominent in patients on rituximab maintenance after R-FC, in whom grade 3-4 leukopenia (up to 40%) and infections were frequent (up to 15%).The excellent results of R-CHOP followed by rituximab maintenance until progression for older patients with MCL persisted in a mature follow-up. Prolongation of rituximab maintenance beyond 2 years is effective and safe.
Acupuncture—A Question of Culture
Authors: Matthias Karst, Changwei Li
Journal: JAMA Network Open (2019)

M. Kay Garcia, DrPH; Zhiqiang Meng, MD; David I. Rosenthal, MD; Yehua Shen, MD; Mark Chambers, DMD; Peiying Yang, PhD; Qi Wei, MS; Chaosu Hu, MD; Caijun Wu, BS; Wenying Bei, BS; Sarah Prinsloo, PhD; Joseph Chiang, MD; Gabriel Lopez, MD; Lorenzo Cohen, PhD
Critical Importance of Conventional Cytogenetics in Detecting Prognostically Significant Chromosome 13 Deletions in Myeloma.
Authors: Laura Chiecchio, Rebecca K.M. Protheroe, Tim Parker, Christina Rudduck, Kan Luk Cheung, Gianpaolo Dagrada, Ashutosh Wechalekar, Mathew Nightingale, Christine J. Harrison, Nicholas C.P. Cross, Fiona M. Ross
Journal: Blood (2005)
Executive task-based brain function in children with type 1 diabetes: An observational study
Authors: Lara C. Foland-Ross, Bruce Buckingam, Nelly Mauras, Ana Maria Arbelaez, William V. Tamborlane, Eva Tsalikian, Allison Cato, Gabby Tong, Kimberly Englert, Paul K. Mazaika, Allan L. Reiss
Journal: PLoS Medicine (2019)

Background Optimal glycemic control is particularly difficult to achieve in children and adolescents with type 1 diabetes (T1D), yet the influence of dysglycemia on the developing brain remains poorly understood. Methods and findings Using a large multi-site study framework, we investigated activation patterns using functional magnetic resonance imaging (fMRI) in 93 children with T1D (mean age 11.5 ± 1.8 years; 45.2% female) and 57 non-diabetic (control) children (mean age 11.8 ± 1.5 years; 50.9% female) as they performed an executive function paradigm, the go/no-go task. Children underwent scanning and cognitive and clinical assessment at 1 of 5 different sites. Group differences in activation occurring during the contrast of "no-go > go" were examined while controlling for age, sex, and scan site. Results indicated that, despite equivalent task performance between the 2 groups, children with T1D exhibited increased activation in executive control regions (e.g., dorsolateral prefrontal and supramarginal gyri; p = 0.010) and reduced suppression of activation in the posterior node of the default mode network (DMN; p = 0.006). Secondary analyses indicated associations between activation patterns and behavior and clinical disease course. Greater hyperactivation in executive control regions in the T1D group was correlated with improved task performance (as indexed by shorter response times to correct "go" trials; r = −0.36, 95% CI −0.53 to −0.16, p < 0.001) and with better parent-reported measures of executive functioning (r values < −0.29, 95% CIs −0.47 to −0.08, p-values < 0.007). Increased deficits in deactivation of the posterior DMN in the T1D group were correlated with an earlier age of T1D onset (r = −0.22, 95% CI −0.41 to −0.02, p = 0.033). Finally, exploratory analyses indicated that among children with T1D (but not control children), more severe impairments in deactivation of the DMN were associated with greater increases in hyperactivation of executive control regions (T1D: r = 0.284, 95% CI 0.08 to 0.46, p = 0.006; control: r = 0.108, 95% CI −0.16 to 0.36, p = 0.423). A limitation to this study involves glycemic effects on brain function; because blood glucose was not clamped prior to or during scanning, future studies are needed to assess the influence of acute versus chronic dysglycemia on our reported findings. In addition, the mechanisms underlying T1D-associated alterations in activation are unknown. Conclusions These data indicate that increased recruitment of executive control areas in pediatric T1D may act to offset diabetes-related impairments in the DMN, ultimately facilitating cognitive and behavioral performance levels that are equivalent to that of non-diabetic controls. Future studies that examine whether these patterns change as a function of improved glycemic control are warranted.
Expression of Erythropoietin Receptor-Like Molecule in Xenopus laevis (xeEPOR) and the Development of Anemia by the Administration of Its Recombinant Soluble Form.
Authors: Youichi Aizawa, Nami Nogawa, Nobuyoshi Kosaka, Yasutaka Maeda, Takafumi Watanabe, Hiroshi Miyazaki, Takahiro Ochiya, Takashi Kato
Journal: Blood (2004)
医生表现的评定与公平性——将利益最大化和危害最小化，必须从一开始就建立起公平原则
Authors: 曾宪嘉（译）, 张孔来（校）
Journal: BMJ (2007)

医生表现的评定现已成为世界范围内临床医师所关注的事实，它包括用一系列标准化指标，对医疗保健质量进行评定和监测。有关医疗保健质量中的缺陷——即在知与行间的差距已有很多文献记载。在与社会性别、种族和社会经济状况相关的可及性、质量及结局等方面，同样也存在着这种不平等的现象并也有所记载。由于对不合乎标准或存在差异的服务质量的认识，对医护人员的公众责任感和卫生系统的改进提出了迫切的要求。
Reduced Inhibitory KIR Receptors in Patients with NK-Lymphoproliferative Disease of Large Granular Lymphocytes (NK-LDGL) Leads to Dysregulated Killing.
Authors: P.K. Epling-Burnette, Fanqi Bai, Jeffrey S. Painter, Sheng Wei, Julie Y. Djeu, Thomas P. Loughran
Journal: Blood (2004)
Long term mortality after severe starvation during the siege of Leningrad: prospective cohort study : British Medical Journal
Authors: P. Sparén, D. Vågero, D. B. Shestov, S. Plavinskaja, N. Parfenova, V. Hoptiar, D. Paturot, M. R. Galanti
Journal: BMJ (2004)

Long term mortality after severe starvation during the siege of Leningrad: prospective cohort study : British Medical Journal
Construction of high quality ultrathin lanthanide oxyiodide nanosheets for enhanced CT imaging and anticancer drug delivery to efficient cancer theranostics
Authors: Lingling Xu, Yumeng Xue, Jiale Xia, Xiaoyan Qu, Bo Lei, Tian Yang, Xiaozhi Zhang, Na Li, Hongyang Zhao, Min Wang, Meng Luo, Chao Zhang, Yaping Du, Chunhua Yan
Journal: Biomaterials (2019)
Risk of Gadolinium-Based Contrast Agents in Chronic Kidney Disease—Is Zero Good Enough?
Authors: Saugar Maripuri, Kirsten L. Johansen
Journal: JAMA Internal Medicine (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Assessment of trimethoprim-sulfamethoxazole susceptibility testing methods for fastidious Haemophilus spp.
Authors: Y. Sierra, F. Tubau, A. González-Díaz, A. Carrera-Salinas, J. Moleres, P. Bajanca-Lavado, J. Garmendia, M. Ángeles Domínguez, C. Ardanuy, S. Martí
Journal: Clinical Microbiology and Infection (2019)
Coronary Disease-Associated Gene <i>TCF21</i> Inhibits Smooth Muscle Cell Differentiation by Blocking the Myocardin-Serum Response Factor Pathway
Authors: Manabu Nagao, Qing Lyu, Quanyi Zhao, Robert C. Wirka, Joetsaroop Bagga, Trieu Nguyen, Paul Cheng, Juyong Brian Kim, Milos Pjanic, Joseph M. Miano, Thomas Quertermous
Journal: Circulation Research (2019)

Rationale: The gene encoding TCF21 (transcription factor 21) has been linked to coronary artery disease risk by human genome-wide association studies in multiple racial ethnic groups. In murine models, Tcf21 is required for phenotypic modulation of smooth muscle cells (SMCs) in atherosclerotic tissues and promotes a fibroblast phenotype in these cells. In humans, TCF21 expression inhibits risk for coronary artery disease. The molecular mechanism by which TCF21 regulates SMC phenotype is not known. Objective: To better understand how TCF21 affects the SMC phenotype, we sought to investigate the possible mechanisms by which it regulates the lineage determining MYOCD (myocardin)-SRF (serum response factor) pathway. Methods and Results: Modulation of TCF21 expression in human coronary artery SMC revealed that TCF21 suppresses a broad range of SMC markers, as well as key SMC transcription factors MYOCD and SRF, at the RNA and protein level. We conducted chromatin immunoprecipitation-sequencing to map SRF-binding sites in human coronary artery SMC, showing that binding is colocalized in the genome with TCF21, including at a novel enhancer in the SRF gene, and at the MYOCD gene promoter. In vitro genome editing indicated that the SRF enhancer CArG box regulates transcription of the SRF gene, and mutation of this conserved motif in the orthologous mouse SRF enhancer revealed decreased SRF expression in aorta and heart tissues. Direct TCF21 binding and transcriptional inhibition at colocalized sites were established by reporter gene transfection assays. Chromatin immunoprecipitation and protein coimmunoprecipitation studies provided evidence that TCF21 blocks MYOCD and SRF association by direct TCF21-MYOCD interaction. Conclusions: These data indicate that TCF21 antagonizes the MYOCD-SRF pathway through multiple mechanisms, further establishing a role for this coronary artery disease-associated gene in fundamental SMC processes and indicating the importance of smooth muscle response to vascular stress and phenotypic modulation of this cell type in coronary artery disease risk.
Engaging with GMC process reduces severity of sanctions, study suggests
Authors: Clare Dyer
Journal: BMJ (2019)

Doctors’ age, race, sex, or country of qualification play no role in deciding the seriousness of penalties imposed by medical practitioner tribunals, a study commissioned by the General Medical Council (GMC) has concluded.1

The strongest factor in determining whether doctors are struck off or suspended, or whether they receive some lesser sanction instead, is the extent to which they engage in the process, …
Dose Intensive Induction Chemotherapy Does Not Decrease Tumor Contamination of Autograft or Improve Survival for Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplant.
Authors: Farzana A. Sayani, Nizar J. Bahlis, Peter Faris, Mary Lynn Savoie, Ahsan Chaudhry, Oluyemi Jeje, Christopher B. Brown, James A. Russell, Douglas A. Stewart
Journal: Blood (2005)
Malignant Atrophic Papulosis
Authors: Adrien Mareschal, Jérôme Razanamahery, François Aubin
Journal: JAMA Dermatology (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal
Significance of Rising Levels of Minimal Residual Disease in Patients with Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia (Ph+ CML) in Complete Cytogenetic Response (CGCR)
Authors: Hagop M Kantarjian, Jianqin Shan, Dan Jones, Susan O’Brien, Mary Beth Rios, Elias Jabbour, Jorge Cortes
Journal: Blood (2008)
Spontaneous hyperinflation of intragastric balloon: What caused it?
Authors: Gontrand Lopez-Nava, Ravishankar Asokkumar, Inmaculada Bautista, Anuradha Negi
Journal: Endoscopy (2019)

Intragastric balloons (IGBs) are an established, minimally invasive treatment option for obesity. Multiple studies have shown them to be safe and effective in achieving weight loss at 6 months and 1 year. IGBs with newer designs, various filling volumes, and longer indwelling times are currently becoming available to minimize intolerance and improve patient adherence [1]. The overall reported rate of complications with IGBs is very low. However, when a complication does occur, it can be severe and debilitating [2]. In this video, we describe a relatively under-reported complication of IGBs.
Safety and Efficacy of Intra-arterial Urokinase After Failed, Unsuccessful, or Incomplete Mechanical Thrombectomy in Anterior Circulation Large-Vessel Occlusion Stroke
Authors: Johannes Kaesmacher, Sebastian Bellwald, Tomas Dobrocky, Thomas R. Meinel, Eike I. Piechowiak, Martina Goeldlin, Christoph C. Kurmann, Mirjam R. Heldner, Simon Jung, Pasquale Mordasini, Marcel Arnold, Pascal J. Mosimann, Gerhard Schroth, Heinrich P. Mattle, Jan Gralla, Urs Fischer
Journal: JAMA Neurology (2019)

Achieving complete reperfusion is a key determinant of good outcome in patients treated with mechanical thrombectomy (MT). However, data on treatments geared toward improving reperfusion after incomplete MT are sparse.